FDC Limited has appointed Mr. Kishore Mukund Saletore as an Independent Director after shareholders approved the proposal through a postal ballot. The resolution received 99.76% votes in favour, with 127,475,844 shares supporting the appointment against 292,160 shares opposing it. The remote e-voting process commenced on April 28, 2026, and concluded on May 27, 2026.

The appointment was approved via a special resolution under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sanjay Dholakia, Practicing Company Secretary and Proprietor of M/s. Sanjay Dholakia & Associates, served as the scrutinizer for the e-voting process. The record date for determining shareholder eligibility was April 17, 2026.

Voting Results Summary

The following table details the voting pattern across different shareholder categories:

Procedural Details

The postal ballot notice was sent to members whose names appeared in the Register of Members as on the cut-off date of April 17, 2026. The e-voting module, provided by NSDL, was disabled on May 27, 2026, at 5:00 p.m., following which the scrutinizer unblocked the votes in the presence of two witnesses not employed by the company. The scrutinizer's report confirms that the special resolution was passed with the requisite majority.

The electronic data and relevant records relating to the remote e-voting have been handed over to Ms. Varsharani Katre, Company Secretary and Compliance Officer of FDC Limited, for safe custody. The appointment is effective from the date of passing the resolution, May 27, 2026.

FDC Limited has received an Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Cefixime for Oral Suspension USP, available in two strengths — 100 mg/5 mL and 200 mg/5 mL. The development was disclosed to stock exchanges on 18 May 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and adds to the company's growing product portfolio in the U.S. pharmaceutical market.

ANDA Approval Details

The approval covers Cefixime for Oral Suspension USP in both available strengths, as outlined below:

Expanding U.S. Market Presence

The USFDA ANDA approval for Cefixime for Oral Suspension USP in both 100 mg/5 mL and 200 mg/5 mL strengths represents a notable development for FDC Limited as it continues to build its regulated market portfolio. Cefixime is a broad-spectrum antibiotic commonly used in the treatment of bacterial infections, and its oral suspension form is particularly relevant for pediatric and adult patients requiring liquid dosage formulations. The approval reflects the company's ongoing commitment to meeting U.S. regulatory standards and broadening its therapeutic offerings in one of the world's most competitive pharmaceutical markets. The intimation was signed by Varsharani Katre, Company Secretary & Legal Head (Membership No. F-8948), on behalf of FDC Limited.